Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
Recruiting · NCT05145816 · Registry updated 2026-08-19Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis | Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell neoplasm, proteostasis deficiencies | Recruiting | Phase 1 / Phase 2 | 2026-08-19 | NCT05145816 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| GlaxoSmithKline | 294 |
| University of Texas Southwestern Medical Center | 295 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Huntsman Cancer Institute, University of Utah | Salt Lake City | United States | 45 |
| UT Southwestern Medical Center | Dallas | United States | 210 |
| Vanderbilt Ingram Cancer Center | Nashville | United States | 13 |